JP2020530472A - シュニッツラー症候群の治療方法 - Google Patents

シュニッツラー症候群の治療方法 Download PDF

Info

Publication number
JP2020530472A
JP2020530472A JP2020507622A JP2020507622A JP2020530472A JP 2020530472 A JP2020530472 A JP 2020530472A JP 2020507622 A JP2020507622 A JP 2020507622A JP 2020507622 A JP2020507622 A JP 2020507622A JP 2020530472 A JP2020530472 A JP 2020530472A
Authority
JP
Japan
Prior art keywords
dapanstryl
syndrome
schnitzler
symptoms
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020507622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530472A5 (https=
Inventor
エー．ディナレロ チャールズ
エー．ディナレロ チャールズ
Original Assignee
オラテック セラピューティクス リミティド ライアビリティ カンパニー
オラテック セラピューティクス リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オラテック セラピューティクス リミティド ライアビリティ カンパニー, オラテック セラピューティクス リミティド ライアビリティ カンパニー filed Critical オラテック セラピューティクス リミティド ライアビリティ カンパニー
Publication of JP2020530472A publication Critical patent/JP2020530472A/ja
Publication of JP2020530472A5 publication Critical patent/JP2020530472A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020507622A 2017-08-11 2018-08-08 シュニッツラー症候群の治療方法 Pending JP2020530472A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762544617P 2017-08-11 2017-08-11
US62/544,617 2017-08-11
PCT/US2018/045752 WO2019032672A1 (en) 2017-08-11 2018-08-08 METHOD OF TREATING SCHNITZLER SYNDROME

Publications (2)

Publication Number Publication Date
JP2020530472A true JP2020530472A (ja) 2020-10-22
JP2020530472A5 JP2020530472A5 (https=) 2021-09-24

Family

ID=65271433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020507622A Pending JP2020530472A (ja) 2017-08-11 2018-08-08 シュニッツラー症候群の治療方法

Country Status (5)

Country Link
US (1) US20200170990A1 (https=)
EP (1) EP3664786B1 (https=)
JP (1) JP2020530472A (https=)
AU (1) AU2018313164A1 (https=)
WO (1) WO2019032672A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045009A4 (en) * 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER
US20230330054A1 (en) * 2020-03-31 2023-10-19 Olatec Therapeutics Llc Method for preventing or treating lung infection and lung inflammation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503533A (ja) * 2010-12-15 2014-02-13 オラテック インダストリーズ リミティド ライアビリティ カンパニー 炎症及び疼痛を処置するための３‐メタンスルホニルプロピオニトリル
JP2016522831A (ja) * 2013-05-21 2016-08-04 ヴァージニア コモンウェルス ユニバーシティ 炎症を予防および治療するためのクリオピリン阻害剤
WO2017031161A1 (en) * 2015-08-17 2017-02-23 Twi Biotechnology, Inc. Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex
WO2017079352A2 (en) * 2015-11-04 2017-05-11 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2970485T3 (es) * 2017-01-06 2024-05-29 Olatec Therapeutics Llc Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503533A (ja) * 2010-12-15 2014-02-13 オラテック インダストリーズ リミティド ライアビリティ カンパニー 炎症及び疼痛を処置するための３‐メタンスルホニルプロピオニトリル
JP2016522831A (ja) * 2013-05-21 2016-08-04 ヴァージニア コモンウェルス ユニバーシティ 炎症を予防および治療するためのクリオピリン阻害剤
WO2017031161A1 (en) * 2015-08-17 2017-02-23 Twi Biotechnology, Inc. Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex
WO2017079352A2 (en) * 2015-11-04 2017-05-11 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNALS OF THE RHEUMATIC DISEASES, vol. Vol.76, Issue Suppl.2, JPN6022016104, 14 July 2017 (2017-07-14), pages 89 - 0090, ISSN: 0004931834 *
OLATECホームページ，[ONLINE], JPN6022016103, 5 April 2017 (2017-04-05), ISSN: 0004931835 *

Also Published As

Publication number Publication date
EP3664786B1 (en) 2022-10-05
US20200170990A1 (en) 2020-06-04
EP3664786A4 (en) 2021-03-31
AU2018313164A1 (en) 2020-03-19
EP3664786A1 (en) 2020-06-17
WO2019032672A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
Fellner et al. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris
US7879870B2 (en) Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
JP2025502266A (ja) 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法
JP2025508359A (ja) 化膿性汗腺炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド
US20200170990A1 (en) Method for treating schnitzler's syndrome
Levitt et al. Sulindac-lnduced Stevens-Johnson Toxic Epidermal Necrolysis Syndrome
JP2022551672A (ja) 乳癌治療法
Vachhani et al. Remission of rheumatoid arthritis on brentuximab vedotin
US20260069578A1 (en) Treatment of neutrophilic dermatoses
EP3621628B1 (en) Method for treating multiple sclerosis using arsenic trioxide
JP6049455B2 (ja) 炎症性関節炎を治療するための組成物および方法
WO2021223966A1 (en) Adenomyosis associated infertility and hdac inhibitors
WO2014121020A2 (en) Treatment of psoriasis using helminthic parasite preparations
US20250339442A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
NL2036681B1 (en) Application of Naringin Combined with Rapamycin in the Preparation of Medications for Treating Hyperlipidemia
RU2149005C1 (ru) Способ лечения вирусной и хламидийной инфекции
Jonassen et al. AP1189: A novel oral biased melanocortin agonist with anti-inflammatory and pro-resolving effect for the treatment of rheumatoid arthritis—ACR meeting abstracts
Rudnikowicz et al. Bullous pemphigoid in a young patient with coexisting long-standing psoriasis, successfully treated with methotrexate
Alkanat et al. Dermatologic Reactions Following COVID-19 Vaccination: A Case Series
WO2023232884A1 (en) Treatment of ulcerative colitis comprising vidofludimus or a pharmaceutically acceptable salt thereof
TW202430217A (zh) 用於免疫介導之壞死性肌病變之治療及預防的抗ｃｄ１９結合劑
KR20260023197A (ko) 세사민을 포함하는 아토피성 피부염의 개선 또는 치료용 조성물
CN114796223A (zh) 选择性ezh2抑制剂在制备治疗干燥综合征药物中的应用
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
RU2672555C2 (ru) Комбинация ингибитора pi3 киназы с паклитакселом для использования при лечении или предотвращении рака головы и шеи

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210810

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221129